The Cooper Companies, Inc. (COO) Average EV/EBIT Ratio
The current ev/ebit ratio for The Cooper Companies, Inc. (COO) is 31.25x as of Sunday, June 14, 2026, shown against its trailing averages.
Average EV/EBIT Ratio Chart
COO EV/EBIT Ratio Averages
EV/EBIT RATIO CURRENT
31.25x
EV/EBIT RATIO TTM
23.67x
EV/EBIT RATIO 3Y
31.83x
EV/EBIT RATIO 5Y
35.66x
EV/EBIT RATIO 10Y
37.23x
EV/EBIT RATIO 15Y
32.98x
EV/EBIT RATIO 20Y
30.38x
About The Cooper Companies, Inc.
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Albert G. White